Dyslipidemia refers to abnormalities in lipids and lipoproteins in the circulation and is a key modifiable risk factor for cardiovascular (CV) disease. The most common lipid abnormalities include elevated levels of LDL-cholesterol and/or triglyceride levels. Statins are firmly established as first-line treatment for most patients with dyslipidemia, owing to their proven CV benefits, physician familiarity with the class, and the increased availability of low-priced generic options. However, a lack of high-quality CV outcomes trial data has weakened physicians’ confidence in many nonstatin drug classes, particularly those agents that lower triglyceride levels. Nonetheless, physicians recognize that many statin-treated patients have residual CV risk and consequently use additional therapies, including the efficacious but expensive proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. This report explores the current U.S. prescribing landscape for dyslipidemia and the factors that influence it.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that clients can create specific messaging around these treatment dynamics in order to more effectively increase or defend their market position.
Survey of 52 endocrinologists and 51 cardiologists in the United States.
KEY DRUGS COVERED
Repatha (evolocumab), Praluent (alirocumab), statins, fibrates, ezetimibe (Zetia, generics), bile acid sequestrants, prescription omega-3 fatty acid compounds.